Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
The objective of the study is to identify novel blood markers for the diagnosis of liver cancer. We will collect serum samples from consented patients and measure the levels of potential protein markers in their serum.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma|
|Study Start Date:||November 2004|
|Estimated Study Completion Date:||December 2018|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Liver cancer is a deadly cancer that is typically hard to diagnose and treat. The currently used blood marker for the clinical diagnosis of liver cancer is alpha-feto protein (AFP), which misses 40-60% of patients with liver cancer because it lacks sufficient specificity and sensitivity. The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with AFP. The aim of this study is to identify new blood markers of liver cancer that can be used to increase the rate of accurate diagnosis of this malignancy.
|United States, California|
|Stanford University School of Medicine||Recruiting|
|Stanford, California, United States, 94305|
|Contact: Mei-Sze Chua 650-724-3525 email@example.com|
|Contact: Cancer Clinical Trials Office (650) 498-7061|
|Principal Investigator: Samuel So|
|Principal Investigator:||Samuel So||Stanford University|